Ehrlichia canis antibody and antigen (recombinant protein)

Diagnostic anti-Ehrlichia canis antibodies pairs and antigen for animal health (animal Cat/Feline, Dog/Canine infectious disease Ehrlichiosis) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT

Target products collectionGo to Companion Animal disease testing products collection >>


Product information

Catalog No. Description US $ Price (per mg)
GMP-VT-P029-Ag01 Recombinant Ehrlichia canis protein $3090.00
GMP-VT-P029-Ab01 Anti-Ehrlichia canis mouse monoclonal antibody (mAb) $3090.00
GMP-VT-P029-Ab02 Anti-Ehrlichia canis mouse monoclonal antibody (mAb) $3090.00

Size: 1mg | 10mg | 100mg



Product Description

Cat No. GMP-VT-P029-Ag01
Product Name Recombinant Ehrlichia canis protein
Pathogen Ehrlichia canis
Expression platform E.coli
Isotypes Recombinant Antigen
Bioactivity validation Anti-Ehrlichia canis antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Ehrlichia canis level test of animal Cat/Feline, Dog/Canine infectious disease with Ehrlichiosis.
Tag His
Product description Recombinant Ehrlichia canis proteinwas expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity Purity: ≥95% (SDS-PAGE)
Application Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Cat No. GMP-VT-P029-Ab01,GMP-VT-P029-Ab02
Pathogen Ehrlichia canis
Product Name Anti-Ehrlichia canis mouse monoclonal antibody (mAb)
Expression platform CHO
Isotypes Mouse IgG
Bioactivity validation Recombinant Ehrlichia canis antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Ehrlichia canis antibodies in Ehrlichia canis level test of animal Cat/Feline, Dog/Canine infectious disease with Ehrlichiosis.
Product description Anti-Ehrlichia canis mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Ehrlichia canis antibodies./td>
Purity Purity: ≥95% (SDS-PAGE)
Application Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Reference




    Validation Data


    Click to get more Data / Case study about the product.



    Pathogen


    Ehrlichia canis, a gram-negative, obligate intracellular bacterium, is a member of the family Anaplasmataceae within the order Rickettsiales. This bacterium is transmitted to dogs through tick bites, primarily by the brown dog tick (Rhipicephalus sanguineus). Canine monocytic ehrlichiosis is caused by Ehrlichia canis, which is known for its ability to infect monocytes and macrophages.

    The genome of Ehrlichia canis contains 1,358 genes, including those involved in DNA replication, transcription, and translation, such as the 16S rRNA gene which plays a role in protein synthesis. The bacterium also encodes virulence factors such as the p28-Omp19 protein, which contributes to its pathogenesis. The lipopolysaccharide (LPS) of Ehrlichia canis has been shown to be toxic to host cells and may play a key role in the development of clinical signs.

    Canine monocytic ehrlichiosis caused by Ehrlichia canis is characterized by acute and chronic phases. The acute phase typically lasts 2-4 weeks and is characterized by fever, anorexia, lethargy, weight loss, and lymphadenopathy. During this time, the bacterium infects and replicates within monocytes and macrophages, leading to systemic inflammation and the release of proinflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α). In the chronic phase, which may last for months or even years, the bacterium persists in the host's body and can cause immune-mediated disease such as thrombocytopenia, anemia, and polyarthritis.

    In addition to dogs, Ehrlichia canis can also infect humans and other mammals. In humans, it is known to cause human monocytic ehrlichiosis (HME), which shares similar symptoms with canine monocytic ehrlichiosis. However, the incidence of HME is rare and the disease is typically self-limiting.

    Diagnostic methods for Ehrlichia canis include serological tests, PCR, and sequencing of the 16S rRNA gene. Serological tests such as the indirect fluorescent antibody (IFA) test and the enzyme-linked immunosorbent assay (ELISA) are commonly used to detect Ehrlichia canis-specific antibodies in the patient's serum. PCR and sequencing of the 16S rRNA gene are highly sensitive and specific methods that can detect the presence of Ehrlichia canis DNA in blood, tissue, or tick samples. Other genes and proteins targeted by diagnostic methods include the dsb gene and the groEL gene.

    In conclusion, Ehrlichia canis is a significant pathogen that infects dogs, humans, and other mammals through tick bites. It causes canine monocytic ehrlichiosis, which manifests as an acute and chronic inflammatory disease. Diagnostic methods such as serological tests, PCR, and sequencing of the 16S rRNA gene enable accurate diagnosis and management of this disease. More research is needed to understand the molecular mechanisms of Ehrlichia canis pathogenesis and to develop effective preventive measures and treatment options for this important zoonotic disease.



    About GDU


    GDU

    GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.